Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells 119,805 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 119,805 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $0.42, for a total value of $50,318.10. Following the transaction, the director now directly owns 3,568,274 shares in the company, valued at $1,498,675.08. This trade represents a 3.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The shares were sold at an average price of $0.54, for a total transaction of $45,261.18.
• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The shares were sold at an average price of $0.45, for a total transaction of $34,099.20.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Stock Performance

IVVD opened at $0.51 on Friday. The stock has a fifty day moving average of $0.73 and a 200-day moving average of $0.98. The company has a market capitalization of $61.00 million, a P/E ratio of -0.26 and a beta of 0.53. Invivyd, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $5.20.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on IVVD shares. D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Invivyd in a research note on Thursday, November 21st. HC Wainwright dropped their price objective on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Morgan Stanley lowered their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $7.89.

Institutional Trading of Invivyd

Several hedge funds and other institutional investors have recently bought and sold shares of IVVD. Barclays PLC grew its position in shares of Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after purchasing an additional 75,780 shares in the last quarter. State Street Corp grew its position in Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after buying an additional 35,904 shares in the last quarter. Proficio Capital Partners LLC bought a new position in Invivyd during the 3rd quarter worth $27,000. Cubist Systematic Strategies LLC raised its holdings in Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after acquiring an additional 53,499 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Invivyd during the 2nd quarter valued at $115,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.